Antigenics posts positive herpes drug study data
Antigenics reported positive data Tuesday from an early stage clinical therapy trial to treat herpes simplex virus-2, the virus that causes genital herpes.
The trial was designed to evaluate a drug designated AG-707, which is designed to stimulate two types of T cells. Antigenics enrolled 35 patients in the trial. They received either AG-707, a combination of AG-707 and an adjuvant called QS-21, QS-21 alone, or a placebo.
The trial was designed to evaluate a drug designated AG-707, which is designed to stimulate two types of T cells. Antigenics enrolled 35 patients in the trial. They received either AG-707, a combination of AG-707 and an adjuvant called QS-21, QS-21 alone, or a placebo.
posted by blog manager at
6:42 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home